So rapidly that it has become imperative for the global community to notice and acknowledge its emergence on the global stage as an economy that counts," Dr Manmohan Singh said inaugurating last evening the three-day conference of the 'Fortune Global Forum.' The prime minister said the road to reform over the past two decades has been a one way street. Different political parties of different ideological hues have been in office over the past two decades.
CCI is India's competition regulator. The undertaking will be a part of the CCI's proposed 'competition compliance' programme.
Rediff reader K Srinivasan, 54 who works as associate general manager, corporate relations at BGS Gleneagles Global Hospitals in Bengaluru shares his story.
However, unlike exports of other goods, which have been affected by the economic slowdown, the reason for fall in exports of opium is entirely different. India is the only country in the world to legally produce gum opium for export, for the pharmaceutical industry. However, exports to the US and Japan, the main importers, have been falling for the past couple of years.
The total incentive outgo under the ambitious production-linked incentive (PLI) scheme is estimated to be less than Rs. 40,000 crore by the fiscal year 2024-25 (FY25), when it completes the fourth year of implementation, according to the government's internal estimates. This means only a fourth of the allocated Rs 1.97 trillion is expected to be utilised by the end of FY24, indicating that not all the 14 PLI schemes would have taken off fully. While three of the 14 schemes - large-scale electronics manufacturing, bulk drugs, and medical devices - were introduced in 2020, the remaining were launched the following year.
The contract research and manufacturing services may soon replace generic drugs manufacturing as the preferred business option for Indian pharmaceutical industry, if growing revenues from CRAMS business is any indication.
The tepid economy has hit most sectors, from automobile and pharmaceutical industries in the district to its tourist footfall, reports Archis Mohan
Sun Pharmaceutical Industries Ltd Chairman Dilip Shanghvi said he expects Ranbaxy Laboratories Ltd to become profitable in the short term.
Sun Pharmaceutical Industries Ltd has posted a net profit of Rs 558.60 million for the quarter ended December 31, 2002 as compared to a net profit of Rs 464.10 million in the corresponding period last fiscal.
rediffGURU Mayank Chandel offers advice to students interested in a careers in science or engineering after class 10 and 12.
'Midcap and smallcap indices are trading in the expensive zone.'
While it is clear the Indian pharmaceutical industry is headed for consolidation, it is not really prepared for it.
The products would be marketed and promoted jointly by Nippon Chemiphar and Nihon Pharmaceutical and sold in Japan under the Ranbaxy/Nihon Pharmaceutical Industry Ltd label.
Government institutions and pharma industry are examining if a 'cocktail' approach to making a multi-variant Covid-19 vaccine works against multiple strains of the ever-mutating virus, reports Sohini Das.
K Anji Reddy from a small village near Vijaywada, quit his job with the government-owned Indian Drugs and Pharmaceuticals Limited in 1974 to set up his own company. The rest is history.
The changes would be immediately effective in countries like Columbia, South Korea, Peru and Panama, where FTAs are in the final stages of approval.
With the new patent regime impending, the focus on the exports market can save Indian companies from any unlikely event post-2005.\n\n\n\n
According to Chinese officials, its current investments in India stands at $1.1 billion, mostly in Gujarat.
The Ernst & Young's first ever healthsciences report has predicted global leadership in vaccines and heightened merger and acquisition activity for the domestic bio-pharmaceutical market.
'Auto, pharma, and industrials have delivered well in the recent quarter, while businesses like quick-service restaurants, consumer staples, and durables have underperformed in volume growth.'
The Indian company that acquires Merck Generics, the multinational drug maker's generics (non-patented) business, up for sale, will be able to compete against the top global players
Since two cases against clinical trials started in SC, govt is overly cautious.
The domestic pharmaceutical industry and non-government organisations are up in arms against the first ever Indo-US tie-up on intellectual property rights
Sun Pharmaceutical Industries and Lupin Ltd will soon add another generic drug each to their US product basket. The companies received approvals from the US drug regulator to market generic equivalent of Pfizer's Dilantin Kapseals and Abbot's Mavik r
The department of personnel and training has asked the Union Public Service Commission to recruit such specialists through "lateral entry" mode in 12 government departments/ministries, he said.
Delegation visit ahead of patent law report.
When John P Kapoor graduated from Bombay University in the 1960s, he had hoped to continue his studies in the United States but could not afford to pay for it. The State University of New York at Buffalo offered him a graduate fellowship.He never forgot his alma mater. In 2000, he gave it $5 million, and, recently, he increased that sum to $10.8 million.
The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.
In a landmark judgment likely to benefit Indian generic drug manufacturers in a big way, the US Supreme Court has ruled against patenting of products with slight modifications.
IIP down due to poor show by manufacturing, mining and power sectors
India will export anti-malarial drug hydroxychloroquine, high in demand globally, only to foreign governments and not to private companies, as the product is under prohibited or banned category of exports, sources said. Although exports of this medicine is completely banned, India has decided to export this anti-malarial drug in sync with its global commitment to deal with the coronavirus pandemic.
Experts say while the increasing demand for a ban on Chinese goods might make for good optics, the reality is that India is still heavily dependent on that country in a wide range of industries like electronics, mobile devices, auto, pharma, telecom equipment, and fertilisers.
The process of discovering and developing a new drug can take decades and costs hundreds of millions or even billions of dollars. However, technological advances like artificial intelligence can help speed up and transform the time-consuming and labor-intensive exercise. In India, Peptris Technologies, a Bangalore-based AI drug discovery company, has announced $1 million in pre-seed round investment led by Speciale Invest.
